Eng-Wong Jennifer, Costantino Joseph P, Swain Sandra M
Department of Internal Medicine, Division of Oncology, Lombardi Cancer Center, Georgetown University, Washington, DC, USA.
J Natl Cancer Inst Monogr. 2010;2010(41):200-3. doi: 10.1093/jncimonographs/lgq021.
Following local therapy for ductal carcinoma in situ (DCIS), tamoxifen reduces the risk of ipsilateral and contralateral breast cancer by 30%-50%. Studies of tamoxifen in women with resected DCIS have not shown any effect on overall or cancer-specific survival. The adverse event profile of tamoxifen is well characterized, and individual risks and benefits should be assessed to guide decision making. We review the results of the phase III trials of tamoxifen in DCIS as well as the emerging risk reduction therapies.
对于导管原位癌（DCIS）进行局部治疗后，他莫昔芬可将同侧和对侧乳腺癌的风险降低30%-50%。对接受DCIS切除术的女性使用他莫昔芬的研究未显示对总生存率或癌症特异性生存率有任何影响。他莫昔芬的不良事件特征已得到充分描述，应评估个体的风险和益处以指导决策。我们回顾了他莫昔芬治疗DCIS的III期试验结果以及新出现的风险降低疗法。
